Skip to content

Linnaeus Therapeutics

6 viewers · 30d

Total raised

$6.3M

+$5.0M this year

5 filings since 2025 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $5.0M
ROUNDS
5
INVESTORS
25
FOUNDED
N/A
HQ
Haddonfield, NJ
SECTOR
Biotechnology
EMPLOYEES
N/A
30D VIEWERS
6

AI overview

Updated

Linnaeus Therapeutics is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for oncology. The company's lead program targets the G protein-coupled estrogen receptor (GPER) to activate tumor-suppressive pathways, aiming to treat cancers like melanoma, particularly in patients who do not respond to existing immunotherapies.

What sets it apart

The company's approach is rooted in discoveries from the University of Pennsylvania, targeting the GPER receptor which is a novel mechanism in oncology. This strategy is coupled with a predictive biomarker to identify patients most likely to benefit, addressing a significant unmet need for those intolerant to traditional immunotherapy.

Funding history

5 rounds
EquityFeb 17, 2026 · $1 min
Form D
+$4.5M$6.3M total
EquityFeb 17, 2026 · $1 min
Form D/A
+$4.8M$6.3M total
EquityFeb 17, 2026 · $1 min
Form D/A
+$4.9M$6.3M total
EquityFeb 17, 2026 · $1 min
Form D/A
+$5.0M$6.3M total
SAFE+1Aug 19, 2025
Form D
+$1.3M$1.3M total

Products

1 tracked

LNS8801

Small-Molecule Therapeutic

LNS8801 is an orally administered, small-molecule agonist of the G protein-coupled estrogen receptor (GPER). It is being developed for cancer treatment and functions by rapidly depleting c-Myc protein levels, leading to antitumor activity and demonstrating target engagement in clinical trials.

  • Oral small-molecule agonist of GPER
  • Rapidly depletes c-Myc protein levels to induce antitumor activity
  • Has shown durable clinical benefit in trials
  • Safe and well-tolerated in clinical studies

Links

WebsiteSEC EDGAR filings